Small-molecule compounds such as inhibitors of heat shock protein 90 and histone deacetylase aim at reducing tumour growth through depletion of mutant p53, while treatment with e.g. PRIMA-1 (2,2-bis (hydroxymethyl)-1-azabicyclo[2,2,2]octan-3-one) reconstitutes wild-type p53 (Parrales & Iwakuma 2015). This evidence concerns the gene TP53 and neoplasm.